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SUMMARY
The aim of this article is to present an investigation of cure rate, after long follow up, of specific chemotherapy with benznidazole
in patients with both acute and chronic Chagas disease, applying quantitative conventional serological tests as the base of the criterion
of cure. Twenty one patients with the acute form and 113 with one or other of the various chronic clinical forms of the disease were
evaluated, after a follow up period of 13 to 21 years, for the acute, and 6 to 18 years, for the chronic patients. The duration of the acute
as well as the chronic disease, a condition which influences the results of the treatment, was determined. The therapeutic schedule was
presented, with emphasis on the correlation between adverse reactions and the total dose of 18 grams, approximately, as well as taking
into consideration precautions to assure the safety of the treatment. Quantitative serological reactions consisting of complement
fixation, indirect immunofluorescence, indirect hemagglutination, and, occasionally, ELISA, were used. Cure was found in 76 per
cent of the acute patients but only in 8 per cent of those with chronic forms of the disease. In the light of such contrasting results,
fundamentals of the etiological therapy of Chagas disease were discussed, like the criterion of cure, the pathogenesis and the role of
immunosuppression showing tissue parasitism in long standing chronic disease, in support of the concept that post-therapeutic
consistently positive serological reactions mean the presence of the parasite in the patient’s tissues. In relation to the life-cycle of T.
cruzi in vertebrate host, there are still some obscure and controversial points, though there is no proof of the existence of resistant or
latent forms. However, the finding over the last 15 years, that immunosuppression brings about the reappearance of acute disease in
long stand chronic patients justifies a revision of the matter. Facts were quoted in favor of the treatment of chronic patients.
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INTRODUCTION
Since 1962, we have examined, at the University Hospital and in
private practice, in Belo Horizonte, MG, Brasil, 2,405 Chagas disease
patients, 47 with the acute form and 2,358 with one of the various chronic
clinical forms of the disease.
The data derived from this work, specially on etiological treatment,
are included in several academic theses and controlled clinical trials,
chapters of books as well as research articles, as cited
elsewhere8,15,16,17,18,19,20,21,37,38,39,49.
The objective of the present article is to evaluate, after a long follow
up period, the results of specific chemotherapy with benznidazole of
patients treated, both during the acute and chronic phase of the disease,
using quantitative conventional serological (CS) tests as the base of the
criterion of cure19.
PATIENTS AND METHODS
PATIENTS. Acute form. Table 1 contains the details of 21 acute
phase of Chagas disease patients, treated with benznidazole, from 1974
to 1982.
Eligible patients included 15 men and 6 women, ranging from 0.7 to
60 years old, who fulfilled two basic conditions:
1. Benznidazole as the only drug used for at least 32 days, consecutively
or with short interval
2. Periodic post-therapeutic examinations availability over a period of
at least 13 years.
All acute patients were admitted to the Hospital, treated and followed
up by the author.
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Chronic form. From among the many hundreds patients treated
during the chronic phase, 113 were selected (tables 2 and 3), who fulfilled
the two following requirements:
1. Benznidazole as the only drug used for at least 40 consecutive days
2. Periodic post-therapeutic examinations availability for 6 to 18 years.
The chronic patients were treated and followed up by the author in
the Outpatient Clinic; 56 were male, 57, female; the youngest was 9
years old and the oldest, 69. The details of clinical forms are listed in
Table 3.
Informed consent was obtained from adults and from the parents, in
case of children.
Therapeutic schedule. A daily dose of benznidazole, varying from
5 to 10 mg/kg/day, was given in equal fractions with intervals of 6, 8 or
12 hours, consecutively or with a short pause. With 73 patients the
treatment was repeated, once, sometimes twice or even three times. The
duration of the treatment was around 40 days, limited by a total dose of
18 grams approximately, a limit beyond which interruption is mandatory,
because of the appearance of sensitive peripheral polyneuritis, a known
toxic side effect of this drug17,18,20.
Adverse reactions. A safe clinical application of benznidazole
demands attention to its various adverse reactions, which we have
described in detail in previous publication18. Here we only mention the
difficulties they raise for the treatment.
Table 1
Long term evaluation of specific treatment with benznidazole of 21 patients of acute Chagas disease
No. Name Age Date of Duration of Dosage Follow-up Results
(years) treatment the disease mg/kg/d (years)
(days) (x days)
7 WRJ 18 1974 40  7 x 65 21 C
8 AAS 18 1974 17  8 x 60
1985 10 y 6.6 x 51 21 F
9 MAB 39 1974 30 6.6 x 60 21 C
13 CMC 16 1974 31  12 x 22
1975 10 m 5 x 60 21 C
15 JBS 0.7 1974 30  30 x 25 c
1979 5 y 14 x 40 21 C
25 RAA 2 1976 20  20 x 19
1979 3 y 5 x 60 19 F
26 ARB 14 1976 29  10 x 40 21 C
27 BFF 38 1976 32 8.2 x 32 20 C
28 SCPL 13 1977 40 8.3 x 40 19 C
30 CMD 23 1978 6 m  5 x 23
1979 1 y 6 m 7.1 x 40 18 C
32 NRT 9 1978 29  10 x 26
1979 11 m 10-20 x 32 17 C
33 JP 0.5 1978 37  18-6 x 60
1986 8 y 6.3 x 70 19 F
34 MVC 60 1978 58  5.2 x 36 9* C
37 WB 27 1979 1 y 3 m 5.5 x 35
1980 2 y 4 m 8.6 x 30 16 C
38 ZKS 35 1979 60 7.5 x 35 13 C
39 IFR 29 1979 40 5.6 x 39
1985 6 y 8 x 33 18 F
40 COC 24 1980 30 8.3 x 40 15 C
41 EFS 25 1980 32  8 x 33
1987 7 y 5.7 x 50 15 F
43 IAS 2 1981 56  20 x 40 14 C
44 LFTS 13 1982 30  10 x 32
1983 1 y 5 m 8 x 35 13 C
45 CNTN 7 1982 20  8 x 40 13 C
Treated: 21 Cured: 16 (76%) 16 5
C, cure; F, failure; y, years; m, months; c, combination. * Died from prostate cancer.
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Dermatitis from hypersensitivity. The most common side effect of
benznidazole is a dermatitis from hypersensitivity, of the serum sickness
type, characterized by cutaneous eruption, generalized edema, fever,
lymphnode enlargement and articular and muscular pain. It appears
around the fifth to the tenth day of treatment, most often in the ninth
day, and is the most relevant adverse reaction to the drug, since it is
common, present in around 20 percent of the patients who receive the
drug, and very often it hinders the treatment. It is an allergic phenomenon,
mediated by IgE, and therefore unpredictable and inevitable. The patients
were advised of this possibility.
Polyneuritis. This is a serious toxic effect induced by benznidazole,
with close connection with its therapeutic index. All patients are
susceptible to it, when the treatment achieves the total dose around 18
grams.
For instance, a dose of 10 mg/kg/day for an adult patient of 60 kg of
weight, i.e., a daily dose of 600 mg, cannot go beyond 30 consecutive
days, when it reaches 18 grams, because symptoms of peripheral
polyneuritis would then arise if not still present. On the other hand, the
same dose of 10 mg/kg/day, given to a child of 20 kg of weight, i.e., a
daily dose of 200 mg, would take 90 days to cause the same effect. That
is why it is said that children tolerate benznidazole better than adults.
This also explains some confusion prevailing in the literature, concerning
the untoward reactions to the drug.
It is interesting to note that patients perceive the first symptoms of
polyneuritis, saying that cutting the nails and washing the hands in cold
water become somewhat painful. Different from the dermatitis, this is a
toxic phenomenon. However, being dose dependent it is preventable.
Depression of bone marrow. Another significant side effect is
depression of bone marrow (neutropenia, agranulocytosis and
thrombocytopenic purpura). Fortunately, the latter two hematological
diseases are extremely rare, according to our experience17,18,20. These
untoward reactions are reversible and corrected safely with corticosteroid
and antibiotic coverage, if infection is present. Since agranulocytosis
can develop rapidly, periodic white-cell counts are of little help. Patients
should be advised that in case of sore throat, and fever, which are the
first symptoms of agranulocytosis, or petechias, specially hemorrhagic
bubles in the oral mucosa, which usually herald the onset of
thrombocytopenic purpura, the drug should be immediately stopped and
the physician informed, who would institute the adequate therapy.
Lymphoma. We have already circumstancially examined the possible
relation between benznidazole and lymphoma, concluding that there was
no reason to stop the clinical use of the drug18. Clinical experience over
the last 30 years in Latin America, where the drug has been extensively
used, did not favor the view that benznidazole therapy is a risk factor for
lymphoma. In the booklet on the etiologic treatment of Chagas disease,
edited by the Brazilian Ministry of Health, with the contribution of several
experts in the field55, the hypothesis of this risk was discarded.
Patient compliance. For the reliable evaluation of the results of
ambulatory treatment, it is imperative to check the full compliance of
the patient to the physician prescription. Every one of our patients
received a printed card where date, dose, time and any abnormal symptom
were recorded and weekly controlled.
Duration of the chronic disease. The duration of the chronic disease
at the beginning of the treatment was determined. This has been an
estimate because the patient usually is unaware of when he was infected,
as the acute phase frequently goes unnoticed. The estimates were based
on the anamnesis and the time elapsed since the patient had moved away
from the endemic area. The minimal duration of the disease could be
determined in 88 of the 113 chronic patients. In 45 cases (52%), the
duration was more than 20 years when treatment was started.
METHODS
Prior to treatment, the patient was subjected to a complete clinical
examination, conventional quantitative serological tests, parasitological
examination, i.e. xenodiagnosis (XD) or hemoculture (HC),
electrocardiogram and x-rays of the thorax (postero-anterior and in profile
with contrasted esophagus).
The conventional quantitative serological tests consisted of
complement fixation (CF)42,58, indirect immunofluorescence (IF)32,48,
indirect hemagglutination (HA)9, and Enzyme-linked Immunosorbent
Assay (ELISA)77.
Table 2
Follow up of 113 patients of chronic Chagas disease treated
with benznidazole
Follow up (years) No. of patients C F D
6 19 1 16 2
7 and 8 22 0 18 4
9 and 10 34 0 33 1
11 and 12 24 3 14 7
13 and 14 10 2 6 2
15 and 16 3 2 0 1
18 1 1 0 0
Total 113 9 87 17
C, cure; F, failure; D, doubtful.
Table 3
Clinical form of 113 patients of chronic Chagas disease treated
with benznidazole
Clinical form No. of patients C F D
Recent 2 2 0 0
Indeterminate 41 1 30 10
Cardiac *
Class I 32 5 24 3
Class II 21 1 17 3
Class III 4 0 4 0
Digestive 6 0 6 0
Cardio-digestive 7 0 6 1
Total 113 9 87 17
* NYHA functional classification. C, cure; F, failure; D, doubtful
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Not every patient was tested by all the above mentioned assays. For
instance, in the first years of the study, serology consisted of quantitative
CF only58. From 1972, quantitative IF and HA tests were added. The
ELISA test was introduced lately.
Parasitological examination was by standardized XD,26 until 1983,
when it was replaced by HC37. The results of these tests were not used as
base of the criterion of cure.
In order to study the dynamics of the serological reversion, in case
of cure of the disease, 11 cured acute patients and 11 cured chronic
patients were selected. The titres of quantitative IF test were chosen to
disclose, by the method of Katan Meier Estimates,47 the fall of the
positivity of serology, following the cure. The results were plotted in
figures 1 and 2, for acute and chronic disease, respectively.
All laboratory tests were done in research institutions (Instituto de
Ciências Biológicas, UFMG, and Centro de Pesquisas René Rachou), in
Belo Horizonte, MG, Brasil, using techniques adopted by their
investigators. During part of the study serum was collected at the hospital
and sent coded to the laboratory for testing.
In general, the drug was bought by the patient, in city drugstores.
RESULTS
Acute disease. The results of the treatment of the 21 patients in the
acute phase of Chagas disease, based in the post-therapeutic quantitative
CF, IF, and HA are summarized in Table 1.
Of the 21 treated patients, 16 (76%) consistently presented negative
serological tests for the follow up period of at least 13 years (patient no.
34 died from prostate cancer after 9 years of follow up), and were
considered cured of the infection. For five patients the serological tests
were persistently positive, indicating treatment failure.
Chronic disease. The results of the treatment of the 113 patients
with different chronic forms of the disease are summarized in Table 4.
For only 9 patients (8%), did post-therapeutic serological tests become
completely and consistently negative, indicating cure.
With 17 patients (15%) the serological tests oscillated between
negative and positive. So they were considered doubtful cases, because
of a possible evolution over the years to persistent negativity.
The remainder 87 patients (77%) had consistently positive post-
therapeutic serological tests, and were classified as treatment failure.
The marked difference between results with acute and chronic cases
is discussed further on.
Recent disease. During the evaluation of the efficacy of the specific
treatment of patients with acute disease (Table 1) we noticed that some
patients (no. 13,15,30,32,37) were cured following the second treatment,
administered up to 5 years after the acute phase. It was a demonstration
that cure was also possible following chronic disease of short
duration17,18,20.
This finding leaded the members of the Symposium on Specific
Treatment, in the II Meeting on Applied Research in Chagas Disease, in
Araxá, MG, in November 1985, to recommend the treatment in recent
chronic infections (in practice, every child with chagasic infection)66.
Though we cannot infer, from our data, the percentage of cure in
recent disease, it is high, close to that observed in acute disease.
Table 4
Results of treatment with benznidazole of 113 chronic patients after
a follow up of six to 18 years
Efficacy No. of patients - (%)
Cure 9 - 8%
Failure 87 - 77%
Doubtful 17 - 15%
Fig. 2 - Katan Meier estimate47 of the fall of the serological IF test positivity in 11 cured
patients with chronic Chagas disease. The median time of cure (50%) occurs at 6 years of the
follow up. At the end of 10 years all patients showed negative serology.
Fig. 1 - Katan Meier estimate47 of the fall of the serological IF test positivity, in 11 cured
patients with acute Chagas disease. The median time of cure (50%) occurs between 11 and
12 months of the follow up. At the end of 14 months all patients showed negative serology
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Controlled clinical trials in Brazil2, Argentina68,69 and Chile65
confirmed the high percentage of cure in children and adolescents, up to
14 years, a fact already observed by pediatricians.
The Brazilian Ministry of Health recommends the specific treatment
in cases of recent infection, including all sero-positive children and
adolescents55.
In congenital disease, which is an acute form of the infection, efficacy
is excellent, cure reaching 100 per cent in children younger than 1 year
and 97% in those up to 3 years29,35,36,56.
Recent disease may be assumed as an asymptomatic acute form.
During how many years, after the infection, the disease may be judged
as early is unknown.
These facts demonstrate that the duration of the infection influences
the therapeutic results.
DISCUSSION
Criterion of cure. Parasitological tests (XD and HC) can be discarded
as base of the criterion of cure of American trypanosomiasis in the chronic
phase of the disease, because they are of low sensitivity and in the long
standing disease they may yield negative results, even when repeated
many times over a long period17,18,19. They cannot be used by themselves,
without taking in account the results of serological tests, to indicate
parasitological cure, as in chronic disease they may only reflect periods
of non-detectable parasitemia12,17. As pointed out a long time ago, they
are aleatory, casual methods75.
On the other hand, serological tests, i.e., the detection of specific
serum antibodies against components of Trypanosoma cruzi, have been
accepted as reliable diagnostic standards, since their introduction in 1913,
by GUERREIRO & MACHADO42,50. Continuous technological
development has resulted in the current range of tests: FC, IF, HA and
ELISA25. These tests use extracts of T. cruzi or the whole parasite as
antigens. They permit screening of blood donors when satisfactorily
standardized14. Besides being the most sensitive and specific method for
the diagnosis of the disease, they are quick, inexpensive, and easy to
execute. They have been widely employed and approved as trustworthy,
since the discovery of the disease. In our experience, the sensitivity of
CF, IF and HA is 91.5%, 99% and 100%, respectively19. Only CF requires
a more refined technology and reagents58, but the other tests in fact suffice
for the purpose at hand. Positive results conclusively demonstrate T.
cruzi infection, i.e., Chagas disease. Therefore, we take them as the base
for evaluation of drug efficacy against T. cruzi infection in humans.
In the last years there have been intensive researches on more defined
and purified antigens for the diagnosis of T. cruzi infection1,62,67,71. Due to
the high complexity of the molecular constitution and antigenic
composition of that parasite, it became clear that single antigens lack the
required sensitivity when compared with conventional tests71. There have
been attempts to increase sensitivity by the use of cocktails of recombinant
antigens67. However, the use of any one of these products is only
recommended, if performed in parallel with one of the conventional tests,
mainly IF or ELISA. Up to now, tests with crude antigens remain indeed
the gold standard for Chagas disease serological diagnosis.
An immunodiagnostic method based on antibody binding to a single
epitope may be of limited usefulness, if the target epitope is not present
in all natural parasite population71.
Another base for the criterion of cure would be the detection of
serum T. cruzi antigen instead of the antibody, a possibility raised today
by the development of the polymerase chain reaction (PCR)10,19.
Results. Concerning the treatment results, we found a high therapeutic
efficacy of benznidazole for acute human Chagas disease, with the cure
of 76 per cent of treated patients. This is in accordance with the experience
of other authors. CERISOLA et al.27 reported negative serology in 80
per cent of 76 treated children, one year after treatment. FERREIRA30
cured seven of ten treated patients and RASSI et al.59 reported 51.6 per
cent of cure rate.
The five patients classified as treatment failures in Table 1 had
uniformely positive CF, IF and HA throughout the follow up period,
even after repetition of therapy. Two of them (no. 8 and 41), developed
cardiomyopathy. The titres of the antibodies detected, though variable
from time to time, remained similar to those prior to therapy.
The most probable cause of the treatment failure in these five patients
is the natural resistance of the strains of Trypanosoma cruzi, a previously
documented phenomenon3,11,33.
In chronic patients cure rate was only 8% (Table 4). Possibly it may
be higher, since some patients of the doubtful group may progress to
persistent CS negativity.
Treatment failure in chronic disease was reported by other
authors34,44,54.
We do not have an incisive interpretation for the remarkable difference
between cure rate in acute (76%) and chronic (8%) disease.
In our judgment, there must be a connection with the fact that, in long
standing chronic Chagas disease, the perpetuation of the infection is due
to the infectivity of the amastigote forms53 in many tissues of the patient,
a state in which complete T. cruzi erradication becomes more difficult.
Serological reversion. In patients cured during the acute phase of
the disease, the median time for the reversion of the serology was between
11 and 12 months after the treatment (Fig. 1), whereas it was of six
years in case of chronic disease (Fig. 2).
It should be noted also that all acute patients showed negative
serology at the end of 14 months, while only after 10 years all chronic
patients displayed negative serology.
In acute Chagas disease similar results have been observed in
Argentina, where 80 percent of 232 acute patients, precociously treated
with nifurtimox, showed serological reversion at the end of six months25.
There is not an adequate explanation for such a long follow up of 10
years, in case of the chronic disease, to have a post-therapeutic serological
reversion. Repetition of the treatment and immune response may be
involved.
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Positive CS demonstrates real parasitism. It has been proposed that
conventional serology would not be a reliable method on which to base
the criterion of cure, because it might not change following the cure of
long standing chronic disease. Possible explanations for such a
phenomenon include immunological memory43,63, auto-immunity45,
sequestration of antigens of T. cruzi in cells of the spleen4, presence of
determinants of carbohydrates derived from intestinal and lung
microflora39, inespecific reactivity due to the use of crude antigens1.
However, if any one of these phenomena prevailed, it would occur in
only a few patients and the tests would show, all along the years, decreasing
or low titres. A comparison in this regard has been invoked with syphilis63.
In this disease the quantitative VDRL titre should return to normal within
12 months of therapy of primary syphilis or 24 months after therapy of
secundary syphilis. Nevertheless, in small percentage of patients with early
syphilis, the VDRL will remain reactive in low titre for long periods of
time43. The situation with long standing Chagas disease is quite distinct.
According to our experience, the post-therapy CS tests maintain, throughout
the years, titres similar to those seen prior to treatment.
Clinical evidence. As we have pointed out previously19, there are
many clinical evidences that the parasite remains in the patient throughout
the entire evolutive process of the disease. For instance, the reactivation
of the infection following heart transplantation in cases of terminal
chronic chagasic cardiomyopathy7,24,72, where the immunosuppressive
drugs used result in the reappearance of T. cruzi in blood and tissues.
Patients exhibit a return to the acute phase of the disease, occasionally
with myocarditis in the allograft. Similarly, non-chagasic patients
submitted to immunosuppressive regimens following organ
transplantation (kidney, heart, pancreas, bone marrow) from sero-positive
donors acquired the infection from the transplanted organ22,28,40.
A further demonstration of the presence of the T. cruzi in chronic
patients is the reactivation of the disease in AIDS sufferers, with
accompanying meningoencephalitis, myocarditis and other lesions, as
well as high parasite burdens31,61.
Another proof of the presence of the parasite in long standing Chagas
disease patients is the finding, by polymerase chain reaction (PCR), of
T. cruzi DNA in the peripheral blood of those patients10, as we have
shown21.
Immunosuppression in chronic Chagas disease patients has revealed
reservoirs of amastigotes in quite distinct organs and tissues, including
the central nervous system, the heart, the skin and the subcutaneous
cellular tissue, the esophagus, the colon, the liver, the bone marrow and
the kidney31. A well-known reservoir of the parasite is the adipose tissue5.
The parasite, which had been occult, disseminates when the strong
and sustained immune response is suppressed. Therefore, it is reasonable
to presume that cure of chronic Chagas disease depends on the
concurrence of chemotherapy and immune response.
Human Chagas disease is a life-long infection50,73. In 45 of 88 treated
chronic patients (52%) we estimated that the duration of the disease was
in excess of 20 years. In the chronic disease, XD positivity may persist
for life. Positive XD has already been documented, in the absence of
reinfection, 35 years after the patients moved to an area where there is
no transmission by the vector64. It is well known that a large proportion
of chronic chagasic patients lives a normal life and are unaware of their
long standing infection. In the absence of a specific serological test,
they are taken as healthy, as evidenced by many cases of acute disease in
nonendemic areas, such as Canada and United States, caused by
transfusion of blood from Latin America immigrants who have lived
there sometimes for more than 20 years40,41,46,57.
There are still some obscure and controversial points concerning the
life-cycle of T. cruzi in vertebrate host. For instance, there is evidence
that trypomastigotes are programmed to develop into amastigotes whether
or not they enter cells and that the differentiation can occur in the blood
of the vertebrate host6. The fact that amastigotes circulate in the
bloodstream contradicts conventional views regarding them as essentially
intracellular. Whether these forms are destined to destruction or play a
role in the parasite life cycle is not known6. There is also evidence that
amastigotes are infective to mice, both in vitro and in vivo23,53, having
already been suggested that they play an important part in the maintenance
of the infection in vivo70. It is not known the relative importance of the
two stages (trypomastigotes and amastigotes) in perpetuating the infection
leading to the chronic phase of the disease53.
Though there is no evidence of resistant or latent forms, the finding,
over the last 15 years, that immunosuppression results in the reappearance
of the acute disease in long standing chronic patients justifies a revision
regarding conventional views on the life cycle of T. cruzi.
Phenomena related to immunoprotection, immunopathogenesis and
autoimmunity are the object of profuse and fascinating research in
experimental models, particularly the mouse. They are also the subject
of much controversy. In human disease these aspects are not yet well
defined13,45,52,60.
FINAL REMARKS
In general, clinical application of benznidazole is a safe procedure if
the physician is aware of the adverse reactions to the drug. Our conclusion
is that it may be used under close supervision, like other drugs with
similar side effects, such as metronidazol51 and the antithyroid
propyltiuracil and metimazole74, that even so are largely applied in clinical
practice.
Considering the severity of Chagas disease, until a better drug is
available, benznidazole should be used also in the treatment of chronic
patients, due to its high efficacy against both the acute and recent disease,
its proved activity in at least 8 per cent of chronic cases, its suppressive
effect of the parasitemia in chronic patients, its possible favorable effect
on the clinical evolution of the disease76, and the fact that it is today one
rational tool available to the physician for specific antichagasic therapy.
Besides, its untoward reactions are well known and can be controlled.
RESUMO
Avaliação a longo prazo do tratamento etiológico da doença de
Chagas com benznidazol
O objetivo deste artigo é verificar o resultado da terapêutica específica
com o benznidazol na doença de Chagas aguda e crônica, após prazo
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longo de seguimento dos pacientes, tomando como base do critério de
cura a reversão pós-terapêutica definitiva à negatividade das reações
sorológicas convencionais quantitativas.
Foram avaliados 21 pacientes agudos e 113 crônicos, em uma ou
outra das diferentes formas clínicas, selecionados por terem sido tratados
somente com o benznidazol e acompanhados por longo tempo, de 13 a
21 anos os agudos e de seis a 18 anos os crônicos.
Expôs-se o esquema terapêutico, dando ênfase à estreita correlação
entre os efeitos colaterais e a dose total de 18 g, aproximadamente, limite
obrigatório porque com essa dose surge a polineurite, se já não estiver
presente. Foram relacionadas algumas precauções para a segurança do
tratamento.
Anotou-se a duração da doença, tanto aguda como crônica,
circunstância que influi no resultado do tratamento.
As reações sorológicas usadas foram a de fixação do complemento,
a de imunofluorescência indireta, a de hemaglutinação indireta, e,
ocasionalmente, a da ELISA.
Verificou-se a cura em 76 por cento dos pacientes agudos e de apenas
8 por cento dos crônicos. Tendo em mente esses resultados, discutiram-
se pontos duvidosos da terapêutica etiológica da doença de Chagas, como
critério de cura, o papel da imunossupressão para o conhecimento da
patogenia da doença e as reações adversas ao medicamento. A hipótese
do autor é que na doença crônica de longa duração o T. cruzi persiste nos
tecidos, após o tratamento, na grande maioria dos doentes tratados,
escapando à ação do medicamento e mantendo positivos os testes
sorológicos.
Relacionam-se razões que justificam o tratamento na doença crônica.
Com relação ao ciclo vital do Trypanosoma cruzi no hospedeiro
vertebrado, há ainda pontos obscuros e controvertidos. Embora não haja
prova da existência de formas resistentes ou latentes, a descoberta, ao
longo dos últimos 15 anos, de que a imunossupressão desencadeia a
doença aguda nos pacientes crônicos de longa duração, justifica revisão
do assunto.
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